Citations (118)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Kristin H. Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, Pauliina Molander, Michael Eberhardson, Loà G. Davidsdottir, Taina Sipponen, Henrik Hjortswang, Guro Løvik Goll, Silje Watterdal Syversen, Ebbe Langholz, Kristin K. Jørgensen & Casper Steenholdt. (2023) Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. Scandinavian Journal of Gastroenterology 58:1, pages 25-33.
Read now
Read now
Gianluca Trifirò, Ilaria Marcianò & Ylenia Ingrasciotta. (2018) Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Expert Opinion on Biological Therapy 18:3, pages 309-315.
Read now
Read now
Mohammed Razvi & Mark Lazarev. (2018) Optimization of biologic therapy in Crohn’s disease. Expert Opinion on Biological Therapy 18:3, pages 263-272.
Read now
Read now
Mônica Simon Prado, Klaus Bendtzen & Luis Eduardo Coelho Andrade. (2017) Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opinion on Drug Metabolism & Toxicology 13:9, pages 985-995.
Read now
Read now
Ahmad Qasem, Abed Elrahman Naser & Saleh A. Naser. (2017) The alternate effects of anti-TNFα therapeutics and their role in mycobacterial granulomatous infection in Crohn’s disease. Expert Review of Anti-infective Therapy 15:7, pages 637-643.
Read now
Read now
Mathurin Flamant, Stephane Paul & Xavier Roblin. (2017) Golimumab for the treatment of ulcerative colitis. Expert Opinion on Biological Therapy 17:7, pages 879-886.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Elena Penza, Ottavia Magnani & Francesco Puppo. (2016) Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. Expert Opinion on Drug Safety 15:1, pages 43-52.
Read now
Read now
Jo Lambert, Alexander Nast, Frank O. Nestle & Jörg C Prinz. (2015) Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?. Journal of Dermatological Treatment 26:6, pages 520-527.
Read now
Read now
Daniël R. Hoekman, Johannan F. Brandse, Tim G. de Meij, Thalia Z. Hummel, Mark Löwenberg, Marc A. Benninga, Geert R. D’Haens & Angelika Kindermann. (2015) The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scandinavian Journal of Gastroenterology 50:9, pages 1110-1117.
Read now
Read now
Morten H. Vatn & Arne K. Sandvik. (2015) Inflammatory bowel disease. Scandinavian Journal of Gastroenterology 50:6, pages 748-762.
Read now
Read now
Klaus Bendtzen. (2012) Anti-TNF-α Biotherapies: Perspectives for Evidence-Based Personalized Medicine. Immunotherapy 4:11, pages 1167-1179.
Read now
Read now
David T. Rubin, Remo Panaccione, Jingdong Chao & Anne M. Robinson. (2011) A practical, evidence-based guide to the use of adalimumab in Crohn’s disease. Current Medical Research and Opinion 27:9, pages 1803-1813.
Read now
Read now
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Ole Østergaard Thomsen & Mark Andrew Ainsworth. (2011) Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scandinavian Journal of Gastroenterology 46:3, pages 310-318.
Read now
Read now
Bernard Bizzini, Béatrice Drouet, Daniel Zagury, Marc Abitbol, Arsène Burny & Marie-Christophe Boissier. (2010) Kinoids: A Family of Immunogens for Active Anticytokine Immunotherapy Applied to Autoimmune Diseases and Cancer. Immunotherapy 2:3, pages 347-365.
Read now
Read now
Lars Aabakken. (2009) This month in the Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology 44:7, pages 772-773.
Read now
Read now
Articles from other publishers (103)
Tsvetelina Velikova, Metodija Sekulovski & Monika Peshevska-Sekulovska. (2024) Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development. Antibodies 13:1, pages 16.
Crossref
Crossref
Krishneel Dutt & Abhinav Vasudevan. (2024) Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. Medicina 60:2, pages 250.
Crossref
Crossref
Abdullah Abbas Awni, Zainab Oday Hamed, Ahmed Abdul-Hassan Abbas & Ahmed Sahib Abdulamir. (2023) Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-α inhibitors in Iraqi patients with rheumatoid arthritis. Heliyon 9:6, pages e16814.
Crossref
Crossref
Ulf Helwig. 2023. Pflege bei chronisch-entzündlichen Darmerkrankungen. Pflege bei chronisch-entzündlichen Darmerkrankungen
79
86
.
Manar Shmais, Miguel Regueiro & Jana G. Hashash. (2022) Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?. Inflammatory Intestinal Diseases 7:1, pages 50-58.
Crossref
Crossref
Farah Albader, Petra Anna Golovics, Lorant Gonczi, Talat Bessissow, Waqqas Afif & Peter Laszlo Lakatos. (2021) Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World Journal of Gastroenterology 27:37, pages 6231-6247.
Crossref
Crossref
José María Giráldez‐Montero, Jaime Gonzalez‐Lopez, Manuel Campos‐Toimil & María Jesús Lamas‐Díaz. (2020) Therapeutic drug monitoring of anti‐tumour necrosis factor‐α agents in inflammatory bowel disease: Limits and improvements. British Journal of Clinical Pharmacology 87:5, pages 2216-2227.
Crossref
Crossref
Antonello Di Paolo & Giacomo Luci. (2021) Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Frontiers in Pharmacology 11.
Crossref
Crossref
Einat Almon, Yoseph Shaaltiel, Wisam Sbeit, Alex Fich, Doron Schwartz, Mattitiahu Waterman, Mali Szlaifer, Hadar Reuveni, Bat-chen Amit-Cohen, Sari Alon, Raul Chertkoff, Alona Paz & Yaron Ilan. (2021) Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis. Journal of Clinical Gastroenterology 55:2, pages 134-140.
Crossref
Crossref
Jacob A. Mojeski & Robert E. Kalb. 2021. Advances in Psoriasis. Advances in Psoriasis
173
199
.
María ChaparroIván Guerra, Marisa Iborra, José Luis Cabriada, Luis Bujanda, Carlos Taxonera, Valle García-Sánchez, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, Isabel Vera, María Dolores Martín-Arranz, Borja Hernández-Breijo, Francisco Mesonero, Laura Sempere, Fernando Gomollón, Joaquín Hinojosa, Fernando BermejoBelén Beltrán, Ainhoa Rodríguez Pescador, Jesús María Banales, David Olivares, Patricia Aguilar-Melero, Luis Menchén, Rocío Ferreiro-Iglesias, Isabel Blazquez Gomez, Belén Benítez García, Luis González Guijarro, Alicia MarinDavid BernardoJavier P. Gisbert. (2020) Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn’s disease. European Journal of Gastroenterology & Hepatology 32:5, pages 588-596.
Crossref
Crossref
Mario RegazziJoseè Golay & Mariadelfina Molinaro. (2020) Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review. Therapeutic Drug Monitoring 42:1, pages 45-56.
Crossref
Crossref
Daniel Bertin, Mélanie Serrero, Jean Charles Grimaud, Ariadne Desjeux & Sophie Desplat-Jégo. (2020) Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits. Cytokine 126, pages 154859.
Crossref
Crossref
Igor Y. Pavlov, Rebecca L. Parker, Eszter Lázár-Molnár, Frederick G. Strathmann & Julio C. Delgado. (2019) Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. Journal of Immunological Methods 470, pages 33-39.
Crossref
Crossref
David Drobne, Tina Kurent, Saša Golob, Polona Švegl, Polona Rajar, Jurij Hanžel, Matic Koželj, Gregor Novak, Nataša Smrekar, Ivan Ferkolj & Borut Štabuc. (2019) Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 49:7, pages 880-889.
Crossref
Crossref
Helena EdlundAna-Marija GrisicCasper Steenholdt, Mark A. Ainsworth, Jørn Brynskov, Wilhelm HuisingaCharlotte Kloft. (2019) Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. Therapeutic Drug Monitoring 41:2, pages 235-242.
Crossref
Crossref
Neil Volk & Corey A Siegel. (2019) Defining Failure of Medical Therapy for Inflammatory Bowel Disease. Inflammatory Bowel Diseases 25:1, pages 74-77.
Crossref
Crossref
Ashish Srinivasan, Nik Sheng Ding, Daniel van Langenberg & Peter De Cruz. 2019. Biomarkers in Inflammatory Bowel Diseases. Biomarkers in Inflammatory Bowel Diseases
243
255
.
Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes & Adriaan A. van Bodegraven. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:9, pages 1075-1106.
Crossref
Crossref
Xavier Roblin, Céline Vérot, Stéphane Paul, Gérard Duru, Nicolas Williet, Gilles Boschetti, Emilie Del Tedesco, Laurent Peyrin-Biroulet, Jean Marc Phelip, Stéphane Nancey & Bernard Flourie. (2018) Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?. Inflammatory Bowel Diseases 24:9, pages 2078-2085.
Crossref
Crossref
Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Alexandra Berrino, Barbara Tolusso, Michele Basile, Laura Cantoro, Paola Balestrieri, Fortunata Civitelli, Lorenzo Bertani, Manuela Marzo, Carla Felice, Elisa Gremese, Francesco Costa, Franca Viola, Michele Cicala, Anna Kohn, Antonio Gasbarrini, Gian Lodovico Rapaccini, Matteo Ruggeri & Alessandro Armuzzi. (2018) Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis.
Crossref
Crossref
Nicholas Carman, David R. Mack & Eric I. Benchimol. (2018) Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports 20:5.
Crossref
Crossref
Séverine Vermeire, Ann Gils, Paola Accossato, Sadiq Lula & Amy Marren. (2018) Immunogenicity of biologics in inflammatory bowel disease. Therapeutic Advances in Gastroenterology 11, pages 1756283X1775035.
Crossref
Crossref
Mathurin Flamant & Xavier Roblin. (2018) Inflammatory bowel disease: towards a personalized medicine. Therapeutic Advances in Gastroenterology 11, pages 1756283X1774502.
Crossref
Crossref
Niels Vande Casteele, Hans Herfarth, Jeffry Katz, Yngve Falck-Ytter & Siddharth Singh. (2017) American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 153:3, pages 835-857.e6.
Crossref
Crossref
Deung Dae Park, Hye-Won Yum, Xiancai Zhong, Seung Hyeon Kim, Seong Hoon Kim, Do-Hee Kim, Su-Jung Kim, Hye-Kyung Na, Atsuya Sato, Takehito Miura & Young-Joon Surh. (2017) Perilla frutescens Extracts Protects against Dextran Sulfate Sodium-Induced Murine Colitis: NF-κB, STAT3, and Nrf2 as Putative Targets. Frontiers in Pharmacology 8.
Crossref
Crossref
Mariam Aguas Peris, Virginia Bosó, Belén Navarro, Maria R. Marqués-Miñana, Guillermo Bastida, Belén Beltrán, Marisa Iborra, Esteban Sáez-González, Emilio Monte-Boquet, Jose L. Poveda-Andrés & Pilar Nos. (2017) Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflammatory Bowel Diseases 23:8, pages 1454-1460.
Crossref
Crossref
Sine Buhl, Casper Steenholdt, Maria Rasmussen, Märta K. Borghede, Jørn Brynskov, Ole Ø. Thomsen & Mark A. Ainsworth. (2017) Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 23:7, pages 1210-1217.
Crossref
Crossref
Einat Almon, Tawfik Khoury, Ariel Drori, Svetlana Gingis-Velitski, Sari Alon, Raul Chertkoff, Mordechai Mushkat, Yoseph Shaaltiel & Yaron Ilan. (2017) An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. Journal of Immunological Methods 446, pages 21-29.
Crossref
Crossref
Mathurin Flamant, Josselin Rigaill, Stephane Paul & Xavier Roblin. (2017) Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects. Drugs 77:10, pages 1057-1068.
Crossref
Crossref
Seoyeon Kim, Byung-Hee Lee, Xiuyu Zhang, Jae-Woo Park, Sle Lee & Hyangsook Lee. (2017) Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis. European Journal of Integrative Medicine 12, pages 12-22.
Crossref
Crossref
Yaron Ilan, Svetlana Gingis-Velitski, Ami Ben Ya’aco, Yehudit Shabbat, Lidya Zolotarov, Einat Almon & Yoseph Shaaltiel. (2017) A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis. Immunobiology 222:3, pages 544-551.
Crossref
Crossref
Manca Ogrič, Matic Terčelj, Sonja Praprotnik, Matija Tomšič, Borut Božič, Snezna Sodin-Semrl & Saša Čučnik. (2016) Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits. Immunologic Research 65:1, pages 172-185.
Crossref
Crossref
Helena Edlund, Casper Steenholdt, Mark A. Ainsworth, Eva Goebgen, Jørn Brynskov, Ole Ø. Thomsen, Wilhelm Huisinga & Charlotte Kloft. (2016) Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn’s Disease Is Determined by Their Concentration. The AAPS Journal 19:1, pages 223-233.
Crossref
Crossref
Eszter Lázár-Molnár & Julio C Delgado. (2016) Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. Clinical Chemistry 62:9, pages 1186-1198.
Crossref
Crossref
Kornelius Schulze, Nadine Koppka, Frederik Lutter, Gunnar Brandhorst, Stefan Schreiber & Ulf Helwig. (2016) CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease. Biologicals 44:5, pages 463-466.
Crossref
Crossref
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov & Mark A. Ainsworth. (2016) Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflammatory Bowel Diseases 22:8, pages 1999-2015.
Crossref
Crossref
G R Gunn, D C F Sealey, F Jamali, B Meibohm, S Ghosh & G Shankar. (2016) From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clinical and Experimental Immunology 184:2, pages 137-146.
Crossref
Crossref
Klaus Bendtzen, Casper Steenholdt, Jørn Brynskov, Ole Ø Thomsen & Mark A Ainsworth. (2016) Monitoring immunogenicity of protein-based TNF antagonists. Frontline Gastroenterology 7:2, pages 152-154.
Crossref
Crossref
Casper Steenholdt, Mehmet Coskun, Sine Buhl, Klaus Bendtzen, Mark A. Ainsworth, Jørn Brynskov & Ole H. Nielsen. (2016) Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease. Medicine 95:16, pages e3417.
Crossref
Crossref
Iris Detrez, Els Brouwers, Miet Peeters, Nick Geukens, Kurt de Vlam & Ann Gils. (2016) Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept. The Journal of Immunology 196:6, pages 2879-2884.
Crossref
Crossref
Gerda C Leitner. (2016) Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World Journal of Gastrointestinal Pharmacology and Therapeutics 7:1, pages 5.
Crossref
Crossref
Chunxiao Wu, Shengxu Wang, Peifeng Xian, Lu Yang, Ying Chen & Xianjie Mo. (2016) Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis. BioMed Research International 2016, pages 1-9.
Crossref
Crossref
Igor Y. Pavlov, James Carper, Eszter Lázár-Molnár & Julio C. Delgado. (2016) Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clinica Chimica Acta 453, pages 147-153.
Crossref
Crossref
Casper Steenholdt, Jørn Brynskov, Ole Ø. Thomsen, Lars K. Munck, Lisbet A. Christensen, Gitte Pedersen, Jens Kjeldsen & Mark A. Ainsworth. (2015) Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn’s Disease. Journal of Crohn's and Colitis 9:11, pages 1032-1042.
Crossref
Crossref
Casper Steenholdt, Jørn Brynskov, Ole Ø. Thomsen, Lars K. Munck, Jan Fallingborg, Lisbet A. Christensen, Gitte Pedersen, Jens Kjeldsen, Bent A. Jacobsen, Anne Sophie Oxholm, Jakob Kjellberg, Klaus Bendtzen & Mark A. Ainsworth. (2015) Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab. Digestive Diseases and Sciences 60:9, pages 2762-2770.
Crossref
Crossref
C Steenholdt & M A Ainsworth. (2015) Authors’ response: Importance of defining loss of response before therapeutic drug monitoring. Gut 64:8, pages 1340-1341.
Crossref
Crossref
W. Moon, L. Pestana, B. Becker, E. V. LoftusJrJr, K. A. Hanson, D. H. Bruining, W. J. Tremaine & S. V. Kane. (2015) Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice. Alimentary Pharmacology & Therapeutics 42:4, pages 428-440.
Crossref
Crossref
Janet R. Wade, Gerry Parker, Gordana Kosutic, Brian G. Feagen, William J. Sandborn, Christian Laveille & Ruth Oliver. (2015) Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. The Journal of Clinical Pharmacology 55:8, pages 866-874.
Crossref
Crossref
Martina Biggioggero, Marco Danova, Umberto Genovese, Francesco Locatelli, Pier Luigi Meroni, Fabrizio Pane & Francesco Scaglione. (2015) The challenging definition of naïve patient for biological drug use. Autoimmunity Reviews 14:6, pages 543-546.
Crossref
Crossref
Joseph D. Feuerstein, Garret Cullen & Adam S. Cheifetz. (2015) Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 21:5, pages 1176-1186.
Crossref
Crossref
Vivian W. Huang, Connie Prosser, Karen I. Kroeker, Haili Wang, Carol Shalapay, Neil Dhami, Darryl K. Fedorak, Brendan Halloran, Levinus A. Dieleman, Karen J. Goodman & Richard N. Fedorak. (2015) Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflammatory Bowel Diseases, pages 1.
Crossref
Crossref
Cheryl Lau, Marla Dubinsky, Gil Melmed, Eric Vasiliauskas, Dror Berel, Dermot McGovern, Andrew Ippoliti, David Shih, Stephan Targan & Phillip Fleshner. (2015) The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery. Annals of Surgery 261:3, pages 487-496.
Crossref
Crossref
C. Steenholdt, K. Bendtzen, J. Brynskov, O. O. Thomsen, L. K. Munck, L. A. Christensen, G. Pedersen, J. Kjeldsen & M. A. Ainsworth. (2015) Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease. Journal of Crohn's and Colitis 9:3, pages 238-245.
Crossref
Crossref
Sung Chul Park & Yoon Tae Jeen. (2015) Current and Emerging Biologics for Ulcerative Colitis. Gut and Liver 9:1, pages 18-27.
Crossref
Crossref
Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Barrett G. Levesque, Séverine Vermeire, William J. Sandborn & Niels Vande Casteele. (2015) Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD. Inflammatory Bowel Diseases 21:1, pages 182-197.
Crossref
Crossref
Sine Schnoor Buhl, Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Klaus Bendtzen & Mark Andrew Ainsworth. (2014) Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open 4:12, pages e005887.
Crossref
Crossref
Madeline Therese Frederiksen, Mark Andrew Ainsworth, Jørn Brynskov, Ole Østergaard Thomsen, Klaus Bendtzen & Casper Steenholdt. (2014) Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD. Inflammatory Bowel Diseases 20:10, pages 1714-1721.
Crossref
Crossref
Subrata Ghosh, Benjamin Pariente, Diane R. Mould, Stefan Schreiber, Joel Petersson & Daniel Hommes. (2014) New tools and approaches for improved management of inflammatory bowel diseases. Journal of Crohn's and Colitis 8:10, pages 1246-1253.
Crossref
Crossref
Julián Panés, Marian O'Connor, Laurent Peyrin-Biroulet, Peter Irving, Joel Petersson & Jean-Frédéric Colombel. (2014) Improving quality of care in inflammatory bowel disease: What changes can be made today?. Journal of Crohn's and Colitis 8:9, pages 919-926.
Crossref
Crossref
Geert R. D'Haens, R. Balfour Sartor, Mark S. Silverberg, Joel Petersson & Paul Rutgeerts. (2014) Future directions in inflammatory bowel disease management. Journal of Crohn's and Colitis 8:8, pages 726-734.
Crossref
Crossref
Cecilia Beatrice Chighizola, Ennio Giulio Favalli & Pier Luigi Meroni. (2013) Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases. Clinical Reviews in Allergy & Immunology 47:1, pages 6-16.
Crossref
Crossref
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Ole Ø Thomsen & Mark A Ainsworth. (2014) Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial. American Journal of Gastroenterology 109:7, pages 1055-1064.
Crossref
Crossref
Angel San Miguel Hernández. (2014) Nuevas contribuciones del laboratorio clínico en el tratamiento de enfermedades inflamatorias crónicas. Revista del Laboratorio Clínico 7:3, pages 85-87.
Crossref
Crossref
Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Bent Ascanius Jacobsen, Anne Sophie Oxholm, Jakob Kjellberg, Klaus Bendtzen & Mark Andrew Ainsworth. (2014) Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63:6, pages 919-927.
Crossref
Crossref
Lawrence B. Cohen, Radu M. Nanau, Faustine Delzor & Manuela G. Neuman. (2014) Biologic therapies in inflammatory bowel disease. Translational Research 163:6, pages 533-556.
Crossref
Crossref
Shomron Ben-Horin & Yehuda Chowers. (2014) Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nature Reviews Gastroenterology & Hepatology 11:4, pages 243-255.
Crossref
Crossref
Pier-Luigi Meroni & Guido Valesini. (2014) Tumour Necrosis Factor α Antagonists in the Treatment of Rheumatoid Arthritis: An Immunological Perspective. BioDrugs 28:S1, pages 5-13.
Crossref
Crossref
Reena Khanna & Brian G. Feagan. (2014) Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. Current Treatment Options in Gastroenterology 12:1, pages 76-89.
Crossref
Crossref
Ana Gutiérrez, Michael Scharl, Laura Sempere, Ernst Holler, Pedro Zapater, Isabel Almenta, José M González-Navajas, José Such, Reiner Wiest, Gerhard Rogler & Rubén Francés. (2014) Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut 63:2, pages 272-280.
Crossref
Crossref
Casper Steenholdt & Klaus Bendtzen. 2014. Autoantibodies. Autoantibodies
803
816
.
Cerrene N. Giordano & Robert E. Kalb. 2014. Advances in Psoriasis. Advances in Psoriasis
177
196
.
R. Khanna, B. D. Sattin, W. Afif, E. I. Benchimol, E.-J. Bernard, A. Bitton, B. Bressler, R. N. Fedorak, S. Ghosh, G. R. Greenberg, J. K. Marshall, R. Panaccione, E. G. Seidman, M. S. Silverberg, A. H. Steinhart, R. Sy, G. Van Assche, T. D. Walters, W. J. Sandborn & B. G. Feagan. (2013) Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 38:5, pages 447-459.
Crossref
Crossref
Paul L. A. M. Corstjens, Herma H. Fidder, Karien C. Wiesmeijer, Claudia J. de Dood, Theo Rispens, Gert-Jan Wolbink, Daniel W. Hommes & Hans J. Tanke. (2013) A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Analytical and Bioanalytical Chemistry 405:23, pages 7367-7375.
Crossref
Crossref
Casper Steenholdt, Mark A. Ainsworth, Michael Tovey, Tobias W. Klausen, Ole Ø. Thomsen, Jørn Brynskov & Klaus Bendtzen. (2013) Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease. Therapeutic Drug Monitoring 35:4, pages 530-538.
Crossref
Crossref
Alexander Eser, Christian Primas & Walter Reinisch. (2013) Drug monitoring of biologics in inflammatory bowel disease. Current Opinion in Gastroenterology 29:4, pages 391-396.
Crossref
Crossref
Yi-Lin Chiu, David T. Rubin, Severine Vermeire, Edouard Louis, Anne M. Robinson, Kathleen G. Lomax, Paul F. Pollack & Susan K. Paulson. (2013) Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease. Inflammatory Bowel Diseases 19:6, pages 1112-1122.
Crossref
Crossref
F. Atzeni, R. Talotta, F. Salaffi, A. Cassinotti, V. Varisco, M. Battellino, S. Ardizzone, F. Pace & P. Sarzi-Puttini. (2013) Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmunity Reviews 12:7, pages 703-708.
Crossref
Crossref
Juan Jose Perez Ruixo, Peiming Ma & Andrew T. Chow. (2012) The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics. The AAPS Journal 15:1, pages 172-182.
Crossref
Crossref
Hidetoshi Takahashi, Hitomi Tsuji, Akemi Ishida‐Yamamoto & Hajime Iizuka. (2012) Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. The Journal of Dermatology 40:1, pages 39-42.
Crossref
Crossref
Yow-Ming C. Wang, Lanyan Fang, Lin Zhou, Jie Wang & Hae-Young Ahn. (2012) A Survey of Applications of Biological Products for Drug Interference of Immunogenicity Assays. Pharmaceutical Research 29:12, pages 3384-3392.
Crossref
Crossref
Casper Steenholdt, Magid Al-khalaf, Jrn Brynskov, Klaus Bendtzen, Ole. Thomsen & Mark A. Ainsworth. (2012) Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 18:12, pages 2209-2217.
Crossref
Crossref
N. Pedersen, M. Elkjaer, D. Duricova, J. Burisch, C. Dobrzanski, N. N. Andersen, T. Jess, F. Bendtsen, E. Langholz, S. Leotta, T. Knudsen, N. Thorsgaard & P. Munkholm. (2012)
eHealth: individualisation of infliximab treatment and disease course via a self‐managed web‐based solution in
C
rohn's disease
. Alimentary Pharmacology & Therapeutics 36:9, pages 840-849.
Crossref
Crossref
Ingrid Ordás, Brian G. Feagan & William J. Sandborn. (2012) Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 10:10, pages 1079-1087.
Crossref
Crossref
Lennard Y.W. Lee, Jeremy D. Sanderson & Peter M. Irving. (2012) Anti-infliximab antibodies in inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 24:9, pages 1078-1085.
Crossref
Crossref
Shui-Long Wang, Linda Ohrmund, Scott Hauenstein, Jared Salbato, Rukmini Reddy, Patrick Monk, Steven Lockton, Nicholas Ling & Sharat Singh. (2012) Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. Journal of Immunological Methods 382:1-2, pages 177-188.
Crossref
Crossref
M. Chaparro, I. Guerra, P. Muñoz‐Linares & J. P. Gisbert. (2012)
Systematic review: antibodies and anti‐
TNF
‐α levels in inflammatory bowel disease
. Alimentary Pharmacology & Therapeutics 35:9, pages 971-986.
Crossref
Crossref
I Ordás, D R Mould, B G Feagan & W J Sandborn. (2012) Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms. Clinical Pharmacology & Therapeutics 91:4, pages 635-646.
Crossref
Crossref
Casper Steenholdt, Magid Al-Khalaf, Mark A. Ainsworth & Jørn Brynskov. (2012) Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. Journal of Crohn's and Colitis 6:3, pages 358-361.
Crossref
Crossref
D. Jullien. (2012) Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis. Annales de Dermatologie et de Vénéréologie 139, pages S58-S67.
Crossref
Crossref
Hirotsugu Imaeda, Akira Andoh & Yoshihide Fujiyama. (2011) Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. Journal of Gastroenterology 47:2, pages 136-143.
Crossref
Crossref
Jean-Frédéric Colombel, Brian G. Feagan, William J. Sandborn, Gert Van Assche & Anne M. Robinson. (2012) Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease. Inflammatory Bowel Diseases 18:2, pages 349-358.
Crossref
Crossref
Frank Hoentjen, Atsushi Sakuraba & Stephen Hanauer. 2012. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
413
432
.
Christophe Lallemand, Nadia Kavrochorianou, Casper Steenholdt, Klaus Bendtzen, Mark A. Ainsworth, Jean-Francois Meritet, Brigitte Blanchard, Pierre Lebon, Peter Taylor, Peter Charles, Saba Alzabin & Michael G. Tovey. (2011) Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. Journal of Immunological Methods 373:1-2, pages 229-239.
Crossref
Crossref
Klaus Bendtzen & Morten Svenson. 2011. Detection and Quantification of Antibodies to Biopharmaceuticals. Detection and Quantification of Antibodies to Biopharmaceuticals
81
101
.
O. H. Nielsen, J. B. Seidelin, L. K. Munck & G. Rogler. (2011) Use of biological molecules in the treatment of inflammatory bowel disease. Journal of Internal Medicine 270:1, pages 15-28.
Crossref
Crossref
C. Steenholdt, M. Svenson, K. Bendtzen, O. Ø. Thomsen, J. Brynskov & M. A. Ainsworth. (2011) Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 34:1, pages 51-58.
Crossref
Crossref
Richard N. Herrier. (2011) Advances in the treatment of moderate-to-severe plaque psoriasis. American Journal of Health-System Pharmacy 68:9, pages 795-806.
Crossref
Crossref
Henit Yanai & Stephen B Hanauer. (2011) Assessing Response and Loss of Response to Biological Therapies in IBD. American Journal of Gastroenterology 106:4, pages 685-698.
Crossref
Crossref
Klaus Bendtzen. (2011) Is there a need for immunopharmacologic guidance of anti–tumor necrosis factor therapies?. Arthritis & Rheumatism 63:4, pages 867-870.
Crossref
Crossref
Kang Cheng & Chang Hua Zou. (2010) Information Models of Acupuncture Analgesia and Meridian Channels. Information 1:2, pages 153-168.
Crossref
Crossref
Klaus Bendtzen. (2010) Critical Review: Assessment of Interferon-β Immunogenicity in Multiple Sclerosis. Journal of Interferon & Cytokine Research 30:10, pages 759-766.
Crossref
Crossref
Thomas W. Lee & Richard N. Fedorak. (2010) Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology. Gastroenterology Clinics of North America 39:3, pages 543-557.
Crossref
Crossref